Revenue segments as reported by the company.

Protein Sciences

Diagnostics and Genomics

lntersegment

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Bio-Techne Corp reports steady Q3 revenue growth amidst China challenges

Bio-Techne Corp reported steady Q3 revenue growth despite challenges in China and temporary headwinds. The company is focused on driving growth in strategic platforms and expanding key franchises. Succession planning and margin improvement are key areas of focus for future growth.

Bio-Techne reports strong Q2 earnings, eyes growth in diagnostics

Bio-Techne's Q2 2023 earnings call highlighted solid performance, strategic strengths in key segments, challenges in ordering patterns, and growth opportunities in diagnostics and research.
The company's focus on innovation, cost management, and strategic investments positions it well for future growth and reaching ambitious revenue targets by FY 2026.
Despite short-term challenges in certain markets, Bio-Techne remains optimistic about its long-term growth prospects and transparent communication with investors.
With a strong financial performance, expanding product portfolio, and a focus on high-growth areas, Bio-Techne is poised for sustained success and market leadership.

Bio-Techne reports solid Q3 performance, eyes growth in key segments

Bio-Techne's Q3 performance showcased strengths in key segments like ExoDx Prostate test demand and GMP proteins, despite challenges in certain markets and OEM destocking dynamics. The company's strategic focus on expanding the Wilson Wolf franchise and driving growth in ACD and key segments like cell and gene therapy position it well for future success. Addressing challenges and capitalizing on growth opportunities will be pivotal for Bio-Techne's continued expansion and market leadership.

Bio-Techne (TECH) excels in Q4, eyes growth amid challenges

Bio-Techne (TECH) reports strong revenue growth and promising future prospects.
Strategic focus on key segments like cell and gene therapy and spatial biology.
Challenges in macroenvironment and funding uncertainties require cautious navigation.
Active M&A strategy and investments to drive growth and market dominance.

Bio-Techne reports steady Q1 growth amid industry challenges

Bio-Techne's Q1 performance showed resilience amidst industry challenges, with a focus on key growth areas and regions. While facing headwinds, the company remains cautiously optimistic about future prospects, emphasizing long-term growth opportunities and productivity measures.

Bio-Techne reports Q2 revenue growth amidst China challenges and opportunities

Bio-Techne's Q2 performance reflects revenue growth and operational efficiency, despite challenges.
Strengths lie in core businesses, Diagnostics and Genomics growth, and record consumables usage in China.
Challenges include market declines, funding constraints, and headwinds in biopharma and academic markets.
Opportunities exist in market normalization, China growth, new product releases, and M&A strategies.

Bio-Techne surpasses Q3 expectations, eyes growth in emerging markets

Bio-Techne's Q3 showcased strong financial performance, with revenue growth and margin expansion across key segments, setting the stage for continued success.
The company's focus on innovation, awards recognition, and strategic market positioning in high-growth areas like cell and gene therapy underpin its competitive strength.
While facing challenges in certain regions and production constraints, Bio-Techne's proactive approach to scaling up manufacturing and diversifying markets positions it well for future growth.
With a clear emphasis on operational efficiency, market expansion, and strategic investments, Bio-Techne is poised for sustained success and value creation for stakeholders.

Bio-Techne reports solid Q4 performance and eyes market recovery

Bio-Techne's Q4 2024 performance reflects resilience and potential for accelerated growth as markets recover in fiscal year 2025.
Strategic leadership additions, productivity initiatives, and market recovery expectations position the company for future success.
Challenges such as capacity constraints and funding environments require strategic management for sustained growth.
Opportunities lie in market recovery, margin improvement, and growth prospects across different segments for Bio-Techne in the coming year.

Bio-Techne reports solid Q1 earnings, eyes growth in biotech markets

Bio-Techne (TECH) delivered solid Q1 2025 results with organic revenue growth, strong segment performances, and a focus on sustainability and strategic partnerships.
While facing challenges in certain markets, the company's emphasis on cost containment and productivity optimization bodes well for future profitability and resilience.
With a positive outlook for growth and opportunities in key segments, Bio-Techne is poised for continued success and market leadership in the biotech industry.
Investors can be optimistic about Bio-Techne's performance, strategic initiatives, and growth prospects, supported by a strong financial foundation and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

MINNEAPOLIS, Jan. 18, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its Stellar NIR / IR™ Detection Modules for Jess.  Stellar fluorescence modules enable detection of low abundance proteins while multiplexing multiple analytes within the same detection lane, setting a new industry standard for western blotting fluorescence detection sensitivity.

BIO-TECHNE ANNOUNCES COMMERCIAL RELEASE OF HIGH SENSITIVITY FLUORESCENT DETECTION STELLAR NIR / IR™ MODULES FOR JESS AUTOMATED WESTERN BLOTTING SYSTEM

MINNEAPOLIS, Jan. 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 1, 2022, at 8:00 a.m. CST to review second quarter fiscal 2022 financial results.

BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2022 TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS

MINNEAPOLIS, Jan. 7, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:15 a.m.

BIO-TECHNE ANNOUNCES UPDATED PRESENTATION TIME AT THE J.P. MORGAN HEALTHCARE CONFERENCE

Akoya Biosciences Inc

MINNEAPOLIS  and MARLBOROUGH, Mass., Jan. 5, 2022 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples.

Bio-Techne and Akoya Biosciences Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution

MINNEAPOLIS, Jan. 3, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 4:30 p.m.

BIO-TECHNE TO PRESENT AT THE J.P. MORGAN HEALTHCARE CONFERENCE

MINNEAPOLIS, Dec. 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Brenda Everson as Senior Vice President, Human Resources effective January 10, 2022. Ms. Everson succeeds Struan Robertson, who will be retiring from the Company.

BIO-TECHNE ANNOUNCES APPOINTMENT OF BRENDA EVERSON AS SVP HUMAN RESOURCES

MINNEAPOLIS, Dec. 21, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3, 2022.

BIO-TECHNE ANNOUNCES APPOINTMENT OF WILL GEIST AS PRESIDENT, PROTEIN SCIENCES SEGMENT

BIO-TECHNE ANNOUNCES FUTURE WILSON WOLF PURCHASE AGREEMENT

MINNEAPOLIS, Dec. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of an important manuscript in the journal Scientific Reports, a Nature Research journal, showing proof-of-concept of its proprietary lateral flow technology. The manuscript is entitled SARS-CoV-2 antigen rapid diagnostic test for resource limited settings.

Bio-Techne Announces Publication of Lateral Flow Technology Proof-of-Concept Data

MINNEAPOLIS, Nov. 22, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at two upcoming investor conferences. Chuck Kummeth, President and Chief Executive Officer will present at the Stephens Annual Investment Conference on Thursday, December 2, 2021 at 4:00 p.m.

Bio-Techne To Present At Upcoming Investor Conferences

ST. PAUL, Minn.--(BUSINESS WIRE)--ScaleReady announced today the launch of a second-generation G-Rex®500M-CS product that is designed to move cell and gene therapy manufacturing to a greater state of practicality and simplicity. ScaleReady is a joint venture founded by Fresenius Kabi, Bio-Techne (NASDAQ: TECH), and Wilson Wolf. “As cell and gene therapies continue to show great lifesaving potential, the need for reliable and automatable closed system cell expansion has never been more important

ScaleReady Launches Second Generation of Wilson Wolf G-Rex Product

MINNEAPOLIS, Nov. 9, 2021  /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:00 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne To Present At The Stifel 2021 Virtual Healthcare Conference

Techne (TECH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Techne (TECH)

Regeneron Pharmaceuticals

REGN vs. TECH: Which Stock Is the Better Value Option?

MINNEAPOLIS, Nov. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene. The AmplideX® PCR/CE CFTR Kit, intended for research use only, provides broader coverage of the diverse U.S. population1,2 than any other commercially available, targeted CFTR testing assay.

Asuragen Launches New Kit to Enable Broader Coverage of Gene Variants Linked to Cystic Fibrosis

MINNEAPOLIS, Nov. 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present virtually at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, November 9, 2021 at 11:20 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne To Present At The Credit Suisse 30th Annual Healthcare Conference

MINNEAPOLIS, Nov. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the commercial availability of GMP-grade materials manufactured at  its St. Paul, MN GMP (Good Manufacturing Practices) manufacturing facility. The facility is dedicated to supporting large-scale production of GMP-grade proteins, including animal-free cytokines and growth factors, that are essential components of cell culture media for immuno-oncology, regenerative medicine and gene-modified cell therapy workflows.

Bio-Techne Announces Commercial Availability Of GMP-Grade Proteins From Dedicated GMP Facility

MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced inclusion in Inc.'s first annual Best-Led Companies list, an exciting 12-point measure of management excellence across the middle market — a select, data-driven list of the very strongest U.S. firms with revenue of $50 million to $2 billion. This novel program is the first Inc. recognition list to honor both public and private companies.

Bio-Techne Named in Inc.'s First-Annual Best-Led Companies

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q1 2022 Results - Earnings Call Transcript

Techne (TECH) delivered earnings and revenue surprises of 3.39% and 1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Q1 Earnings and Revenues Top Estimates

MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2021. First Quarter FY2022 Snapshot First quarter organic revenue increased by 21% (26% reported) to $257.7 million.

Bio-Techne Releases First Quarter Fiscal 2022 Results

Bio-Techne (NASDAQ:TECH) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement.

Bio-Techne's Earnings: A Preview

Fortinet

Alphabet

NVIDIA

Old Dominion Freight Line

In GuruFocus' High Quality Low CAPEX model portfolio, the companies with the biggest year-to-date returns are Fortinet Inc. ( FTNT , Financial), Nvidia Corp. ( NVDA , Financial), Old Dominion Freight Line Inc. ( ODFL , Financial), Alphabet Inc. ( GOOGL , Financial) and Bio-Techne Corp. ( TECH , Financial).

Top-Performing Stocks From the High Quality Low CAPEX Model Portfolio

MINNEAPOLIS, Oct. 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the journal Prostate Cancer and Prostatic Diseases, entitled Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies . In this pooled analysis from three independent prospective-validation studies and more than 1200 subjects, principal investigator Dr. Erik Margolis, Chief of Urology at Englewood Hospital and Medical Center, and colleagues demonstrated the ExoDx Prostate test, or EPI, can discriminate high-grade (≥GG2) from low-grade (GG1) cancer and benign disease.

Bio-Techne Announces ExoDx Prostate Test Data Publication in the Journal of Prostate Cancer and Prostatic Diseases

MINNEAPOLIS, Oct. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 2, 2021, at 8:00 a.m. CDT to review first quarter 2022 financial results.

News for Bio-Techne Stock (TECH)